ArticleInternational journal of molecular sciences2026
DNA Methylation and mRNA Expression of SEPT9 and AKR1B1 in Ovarian Cancer: Diagnostic and Prognostic Implications.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic dysregulation is increasingly recognized as an important contributor to ovarian carcinogenesis, and may provide novel diagnostic and prognostic biomarkers. This study evaluated DNA methylation and mRNA expression of SEPT9 and AKR1B1 in ovarian cancer and benign ovarian lesions and assessed their clinical significance. Tissue samples were obtained from 27 patients with ovarian cancer and 29 patients with benign ovarian lesions. DNA methylation was analyzed by pyrosequencing and mRNA expression by real-time PCR. Associations with clinicopathological variables, serum CA125 and HE4 concentrations, diagnostic performance, and survival outcomes were evaluated. Receiver operating characteristic (ROC) analysis, multivariable logistic regression, Kaplan-Meier analysis, and Cox regression models were performed. Multiple testing was controlled using the Benjamini-Hochberg false discovery rate procedure. Ovarian cancer tissues demonstrated significantly lower SEPT9 methylation (q = 0.008), higher AKR1B1 methylation (q = 0.0008), and lower AKR1B1 mRNA expression (q = 0.035) compared with benign ovarian lesions. SEPT9 methylation showed the highest diagnostic accuracy (AUC = 0.741). Both SEPT9 methylation (OR = 0.92,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.